S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Biocept Stock Forecast, Price & News

+0.06 (+1.54%)
(As of 11/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
258,597 shs
Average Volume
600,358 shs
Market Capitalization
$66.53 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

Biocept logo

About Biocept

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.


Biocept, Inc. (NASDAQ:BIOC) Sees Large Drop in Short Interest
November 21, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$27.46 million
Book Value
$1.77 per share


Net Income
$-17.81 million
Pretax Margin




Free Float
Market Cap
$66.53 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.70 out of 5 stars

Medical Sector

1028th out of 1,390 stocks

Medical Laboratories Industry

24th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept
or view top-rated stocks.

How has Biocept's stock price been impacted by COVID-19 (Coronavirus)?

Biocept's stock was trading at $3.7690 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIOC stock has increased by 4.8% and is now trading at $3.95.
View which stocks have been most impacted by COVID-19

Are investors shorting Biocept?

Biocept saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 461,900 shares, a decrease of 17.9% from the October 14th total of 562,900 shares. Based on an average daily trading volume, of 1,010,000 shares, the days-to-cover ratio is presently 0.5 days.
View Biocept's Short Interest

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Biocept

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.06. The medical research company earned $17.47 million during the quarter, compared to the consensus estimate of $16.87 million. Biocept had a net margin of 4.71% and a trailing twelve-month return on equity of 10.35%. During the same quarter in the prior year, the firm posted ($0.43) EPS.
View Biocept's earnings history

When did Biocept's stock split? How did Biocept's stock split work?

Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for BIOC?

3 equities research analysts have issued 12-month price targets for Biocept's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate Biocept's stock price to reach $20.00 in the next year. This suggests a possible upside of 406.3% from the stock's current price.
View analysts' price targets for Biocept
or view top-rated stocks among Wall Street analysts.

Who are Biocept's key executives?

Biocept's management team includes the following people:
  • Michael W. Nall, President, Chief Executive Officer & Director
  • Timothy C. Kennedy, CFO, Senior VP-Operations & Secretary
  • Lyle J. Arnold, Chief Scientific Officer & Senior Vice President
  • Michael C. Dugan, Chief Medical Officer & Medical Director
  • Michael W. Brown, General Counsel, Compliance & Privacy Officer

What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.89%), Marshall Wace LLP (0.71%), GSA Capital Partners LLP (0.63%), Renaissance Technologies LLC (0.35%), Jump Financial LLC (0.13%) and Goldman Sachs Group Inc. (0.13%).
View institutional ownership trends for Biocept

Which institutional investors are selling Biocept stock?

BIOC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, GSA Capital Partners LLP, and Geode Capital Management LLC.
View insider buying and selling activity for Biocept
or view top insider-selling stocks.

Which institutional investors are buying Biocept stock?

BIOC stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Renaissance Technologies LLC, Jump Financial LLC, Goldman Sachs Group Inc., and Jane Street Group LLC.
View insider buying and selling activity for Biocept
or or view top insider-buying stocks.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $3.95.

How much money does Biocept make?

Biocept has a market capitalization of $66.53 million and generates $27.46 million in revenue each year. The medical research company earns $-17.81 million in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does Biocept have?

Biocept employs 107 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

Where are Biocept's headquarters?

Biocept is headquartered at 5810 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.